A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2019-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Phase 1 of the study is to evaluate the effect of food on the pharmacokinetics (PK) of oprozomib, the drug-drug interaction of oprozomib with midazolam, and the safety and tolerability of oprozomib in patients with advanced malignancies

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

NCT01416428

Multiple Myeloma Waldenstrom Macroglobulinemia

TERMINATED PHASE1/PHASE2

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

NCT03591744

Plasma Cell Leukemia

WITHDRAWN PHASE1

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00577694

Leukemia

TERMINATED PHASE1

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

NCT01003678

Myelodysplastic Syndrome

TERMINATED PHASE1

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00694590

Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Non-Central Nervous System (CNS) Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part I: Food Effect/QTc

Subjects will receive a single dose of oprozomib 270 mg in 1 of 3 fasting/fed conditions:

* Diet A: Fasted conditions
* Diet B: A low-fat breakfast. A low-fat breakfast is defined as having a total caloric value of less than 400 calories, with less than 20% from fat
* Diet C: A high-fat breakfast. A high-fat breakfast is defined as having a total caloric value of 800 to 1000 calories, with approximately 50% from fat

Group Type EXPERIMENTAL

Oprozomib

Intervention Type DRUG

Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.

Part II: Drug-Drug Interaction (DDI)

* Period 1: Midazolam 2 mg single oral dose on one day between Day -7 and -4
* Period 2: Midazolam 2 mg single oral dose 1 hour following oprozomib dose on Day 1 of Cycle 1 and Day 2 of Cycle 2. Oprozomib 300 mg dose on Days 1, 2, 8 and 9 of Cycles 1 and Cycle 2

Group Type EXPERIMENTAL

Oprozomib

Intervention Type DRUG

Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.

Midazolam

Intervention Type DRUG

Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.

Extension

After subjects complete the Food Effect/QTc or DDI part, subjects may participate in the extension part of the study, where oprozomib treatment will be continued on Days 1, 2, 8, and 9 of each 14-day cycle. During this part of the study, it is recommended that oprozomib be taken with food.

Group Type EXPERIMENTAL

Oprozomib

Intervention Type DRUG

Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oprozomib

Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.

Intervention Type DRUG

Midazolam

Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically confirmed diagnosis of an advanced malignancy.
2. Relapsed after standard therapy for their malignancy, or if no standard therapy is defined, relapsed after investigational therapy and considered by the treating physician to be an appropriate candidate for a Phase 1 clinical study
3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
4. Adequate hepatic function, with bilirubin ≤ 1.5 times the upper limit of normal (ULN) in the absence of Gilbert's disease or hemolysis, and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times ULN.
5. Absolute neutrophil count (ANC) ≥ 1000/mm3. Screening ANC must be independent of myeloid growth factor support for at least 1 week, or pegylated growth factors for 2 weeks.
6. Hemoglobin \> 7g/dL. Patients may receive red blood cell (RBC) transfusions or erythropoietin or darbepoetin in accordance with institutional guidelines up to 1 week before screening.
7. Platelet count \> 30,000 mm3. Patients will not have received platelet transfusions for at least 1 week before screening.
8. Uric acid, if elevated, must be lowered to less than the ULN.
9. Calculated or measured creatinine clearance (CrCl) ≥ 30 mL/min calculated using the formula of Cockcroft and Gault \[(140 - age) × mass (kg) / (72 × serum creatinine mg/dL)\]. Multiply result by 0.85 if female.

Exclusion Criteria

1. Recovered (i.e., ≤ Grade 1 toxicity or patient's baseline status) from the reversible nonhematologic effects of prior anticancer therapy, excluding alopecia.
2. Systemic chemotherapy with approved or investigational anticancer therapeutics, including steroid therapy intended to treat underlying malignancy, within 3 weeks before the first oprozomib dose; for antibody therapy, a minimum of 3 half-lives must elapse before the first oprozomib dose.
3. Radiation therapy within 3 weeks before first oprozomib dose. Radioimmunotherapy within 8 weeks before first oprozomib dose.
4. Autologous stem cell transplant (ASCT) within 8 weeks and allogeneic SCT within 16 weeks prior to initiation of study treatment. Patients with prior allogeneic SCT must not have evidence of moderate-to-severe graft-versus-host disease (as defined in Filipovich 2005).
5. Unresolved toxicity (NCI-CTCAE version 4.03) ≥ Grade 2 from previous anticancer therapy, except alopecia.
6. Major surgery within 3 weeks before first oprozomib dose.
7. Congestive heart failure (New York Heart Association Class III to IV)
8. Symptomatic cardiac ischemia.
9. Conduction abnormalities uncontrolled by conventional intervention, including but not limited to persistent or permanent atrial fibrillation.
10. History of ventricular fibrillation or ventricular tachycardia.
11. History of torsade de pointe.
12. Myocardial infarction within 6 months before first dose.
13. Abnormal measurements on 12-lead ECG.
14. Uncontrolled diabetes mellitus or hypertension
15. Dysphagia or inability to swallow tablets.
16. Insufficiency of the exocrine pancreas, steatorrhea, or other disorders of the digestive system that impair absorption.
17. Resection of any portion of the stomach or intestines, with the exception of appendectomy.
18. History of bariatric surgery, except in cases where no bowel was resected and all devices have been removed.
19. Active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks before first dose, unless cultures or polymerase chain reaction (PCR) have been negative for 14 days.
20. Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive, or suspected hepatitis C infection.
21. Primary malignancy of the central nervous system.
22. Patient has symptomatic brain metastasis. Patients with brain metastases must have stable neurologic status following surgery or radiation for at least 2 weeks after completion of the definitive therapy, AND be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
23. Significant peripheral neuropathy (Grade 2 with pain or ≥ Grade 3).
24. Systemic treatment with strong inhibitors of P-glycoprotein (\[P-gp\]; i.e., itraconazole, ketoconazole) within 14 days before the first dose of oprozomib.
25. Patients must not have used any potent CYP3A4 inhibitors (i.e., ketoconazole) within 7 days prior to enrollment, or any potent CYP3A4 inducers (i.e., rifampin) within 14 days prior to enrollment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No